Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Journal Article


Authors: Roobol, M. J.; Kerkhof, M.; Schroder, F. H.; Cuzick, J.; Sasieni, P.; Hakama, M.; Stenman, U. H.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; Denis, L.; Recker, F.; Berenguer, A.; Ruutu, M.; Kujala, P.; Bangma, C. H.; Aus, G.; Tammela, T. L. J.; Villers, A.; Rebillard, X.; Moss, S. M.; De Koning, H. J.; Hugosson, J.; Auvinen, A.
Article Title: Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
Abstract: Background: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa) has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) analysis in a randomised trial (European Randomised Study of Screening for Prostate Cancer [ERSPC]). This effect may be diluted by nonattendance in men randomised to the screening arm and contamination in men randomised to the control arm. Objective: To assess the magnitude of the PCa-specific mortality reduction after adjustment for nonattendance and contamination. Design, setting, and participants: We analysed the occurrence of PCa deaths during an average follow-up of 9 yr in 162 243 men 55-69 yr of age randomised in seven participating centres of the ERSPC. Centres were also grouped according to the type of randomisation (ie, before or after informed written consent). Intervention: Nonattendance was defined as nonattending the initial screening round in ERSPC. The estimate of contamination was based on PSA use in controls in ERSPC Rotterdam. Measurements: Relative risks (RRs) with 95% confidence intervals (CIs) were compared between an ITS analysis and analyses adjusting for nonattendance and contamination using a statistical method developed for this purpose. Results and limitations: In the ITS analysis, the RR of PCa death in men allocated to the intervention arm relative to the control arm was 0.80 (95% CI, 0.68-0.96). Adjustment for nonattendance resulted in a RR of 0.73 (95% CI, 0.58-0.93), and additional adjustment for contamination using two different estimates led to estimated reductions of 0.69 (95% CI, 0.51-0.92) to 0.71 (95% CI, 0.55-0.93), respectively. Contamination data were obtained through extrapolation of single-centre data. No heterogeneity was found between the groups of centres. Conclusions: PSA screening reduces the risk of dying of PCa by up to 31% in men actually screened. This benefit should be weighed against a degree of overdiagnosis and overtreatment inherent in PCa screening. © 2009 European Association of Urology.
Keywords: adult; controlled study; aged; middle aged; major clinical study; clinical trial; prostate specific antigen; controlled clinical trial; randomized controlled trial; randomized controlled trials as topic; cancer screening; risk factor; cancer mortality; prostate cancer; prostate-specific antigen; prostatic neoplasms; statistical analysis; screening; mortality reduction; patient compliance; risk reduction; adjusted analysis; contamination; non compliance
Journal Title: European Urology
Volume: 56
Issue: 4
ISSN: 0302-2838
Publisher: Elsevier Science, Inc.  
Date Published: 2009-10-01
Start Page: 584
End Page: 591
Language: English
DOI: 10.1016/j.eururo.2009.07.018
PUBMED: 19660851
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 38" - "Export Date: 30 November 2010" - "CODEN: EUURA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hans Gosta Lilja
    343 Lilja